BOARD-INTERNATIONAL
Leading Decision-Making Platform Vendor Board International today announced that Giovanni Grossi, Co-Founder and Chief Executive Officer (CEO), has stepped down from his position.
“After more than 25 years building Board International’s success, it’s time to have a rest. I leave a powerful, well-organized company that is achieving outstanding results. We are growing more than 70% against the same period last year, the pipeline is rich, and in April, we are releasing the best version of our platform ever. I want to thank all the people that have shared this adventure with me - it’s a powerful team that I’m sure will continue to drive the company’s success. A special thank you to Maurizio Carli and to Nordic Capital,” comments Giovanni Grossi.
Board continues to drive its international expansion and strengthen its growth trajectory. Mr. Grossi’s succession was planned as part of Nordic Capital’s majority share acquisition of Board International in 2019 and recent increase in share ownership at the end of 2020. Maurizio Carli, Board International’s Chairman, will act as interim CEO to oversee day-to-day operations in a transition period as a successor is recruited. Maurizio will apply more than 30 years of experience in IT leadership and work alongside an Executive Committee consisting of Board’s senior management team.
“I would like to thank Giovanni for having built a very successful company. When working with him over the last couple of years, I have been impressed by both his leadership and his great perspective of the market,” comments Maurizio Carli.
“Nordic Capital would like to thank Giovanni for his dedication and entrepreneurship over the last 27 years as CEO and Co-Founder. Under his leadership, the company has grown to become a global leader in decision-making software, with a presence in 26 countries, an impressive blue-chip customer base, and a very bright future. We wish Giovanni all the best in his future endeavors as we embark on the next stage of Board’s growth and welcome Giovanni continuing to be a partner as a shareholder of Board,” comments Fredrik Näslund, Partner and Head of Technology & Payments, Nordic Capital Advisors [and board member of Board International].
Board continues its successful growth globally, with annual recurring revenue growing 67% on average over the last three years. This is a testament to Board’s superior technology, qualified people, and customer focus.
Fredrik Näslund adds: “Nordic Capital is looking forward to the continued journey ahead with all customers and people at Board.”
About Board
Board is the #1 Decision-Making Platform. Founded in 1994, Board enables people to have a transformative impact on their business, helping them to intuitively explore and leverage their data in a flexible, all-in-one decision-making platform. By unifying business Intelligence, planning, and predictive analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. Thanks to Board, more than 3,000 organizations worldwide, including Coca-Cola, Ricoh, KPMG, Puma, Siemens, and ZF Group, have deployed end-to-end decision-making applications at a fraction of the time and cost associated with traditional solutions. www.board.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005542/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 13:05:00 CEST | Press release
Q-Alliance launch marks a key milestone in Italy’s digital transformation and the country’s ambitious quantum ecosystem goals IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transf
Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 12:01:00 CEST | Press release
Reliable, Quiet Single-Tower Air Coolers Built on Patented 3DHP Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 12:00:00 CEST | Press release
New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show promise in advanced solid tumors BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will b
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 11:00:00 CEST | Press release
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock
New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK20.10.2025 10:01:00 CEST | Press release
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom